Topic
4 articles
A long-standing bureaucratic obstacle to privately-funded medical marijuana research has just been removed, effective immediately. The Department of Health and Human Services determined that the PHS review process is redundant with the FDA review, and that...
Many are screaming "hypocrisy," and with good reason. How can the U.S. government continue to classify cannabis as a Schedule I drug while simultaneously admitting, at last, to its medicinal benefits?
In a move which may have been made in response to federal pressure to expand options for US researchers trying to study the effects of herbal cannabis on the human body, the National Institute on Drug Abuse (NIDA) has announced a wider selection of federally-sanctioned research cannabis, available either in bulk or as individually wrapped cigarettes.
Scientists who study medical marijuana will soon have access to a wider variety of strains. The National Institute of Drug Abuse (NIDA) — the federal "dealer" that supplies the drug to scientists — has received numerous complaints from researchers that the drug they supply is too weak compared with what's sold on the streets, legal or otherwise.
